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Abstract 1 
 Development of autoimmune thyroid disease (AITD) including Graves’ disease (GD) and 2 
Hashimoto’s thyroiditis (HT) is related to expression of HLA-DRB1*0301(DR3).  The 3 
extracellular domain (ECD) of human TSH receptor (hTSH-R) is a crucial antigen in GD.  hTSH-4 
R peptide 37 (AA 78-94) is an important immunogenic peptide in DR3 transgenic mice. 5 
 In the current study, DR3 transgenic mice were immunized to recombinant hTSH-R-ECD 6 
protein or peptides.  Serum anti hTSH-R protein antibody, or anti hTSH-R peptide antibodies were 7 
titrated by ELISA.  Further, a mutant hTSH-R 37 (ISRIYVSIDATLSQLES: 37m), in which DR3 8 
binding motif position 5 was mutated V>A, and position 8 Q>S, was synthesized.  37m was 9 
predicted to bind to HLA-DR3, but not bind to T-cell receptors.  DR3 transgenic mice were 10 
immunized to hTSH-R 37 and 37m. 11 
  Mice immunized to hTSH-R-ECD protein developed strong anti hTSH-R antibody, and 12 
the antisera reacted strongly with hTSH-R peptides 1 to 5 (AA 20-94), sequences recognized as B-13 
cell epitopes that reacted with human TRAb.  In addition, the antisera recognized hTSH-R 14 
peptides 21(258-277), 41(283-297), 36(376-389), and 31(399-418).  Strikingly, antisera raised to 15 
hTSH-R peptide 37 bound hTSH-R peptides 1-7(AA 20-112), 10(132-50), 33(137-150), 41, 16 
23(286-305), 24(301-320), 36, and 31, as well as to hTSH-R-ECD protein.  Both antibody titers to 17 
hTSH-R 37, and reaction of splenocytes to hTSH-R 37, were significantly reduced in mice 18 
immunized to hTSH-R 37 plus 37m, compare to mice immunized to hTSH-R 37 alone. 19 
 Binding of anti hTSH-R antibodies to the amino-terminal end of the ECD was confirmed in 20 
our DR3 transgenic mice.  The ability of immunization to a single peptide to induce antibodies that 21 
bind hTSH-R-ECD protein, as well as multiple unrelated peptides, is a unique observation.  The 22 
mechanism may relate to TSH-R epitope spreading.  Immunogenic reaction to hTSH-R peptide 37 23 
could be partially suppressed by 37m, and this might contribute to immunotherapy of AITD. 24 
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Introduction 1 
 Autoimmune thyroid disease (AITD) is an organ specific autoimmune disease.  Graves’ 2 
disease (GD) and Hashimoto’s thyroiditis (HT) are the major components of AITD. Thyrotropin 3 
receptor (TSH-R) is one of the well-known target antigens in GD, and also often serves as antigen 4 
in HT( 1 ).  Ectodomain of TSH-R (TSH-R-ECD) mediates various immune responses in the 5 
development of GD ( 2 ), and multiple epitopes are thought to exist( 3-6 ). 6 
 Shed TSH-R-ECD is endocytosed into antigen presenting cells (APCs), and processed to be 7 
presented on the surface of APCs as HLA-DR-epitope complexes.  These complexes 8 
arerecognized by CD4+ T-cells and positive signals for B-cell proliferation aretransmitted.  9 
Subsequently, anti-TSH-R antibody is secreted by B-cells.  Hyperthyroidism is induced by anti 10 
TSH-R antibody that stimulates TSH-R.  HLA-DRB1*0301(DR3)( 7 ), CTLA-4( 8 ), TSH-R( 9 ), 11 
FCRL3( 10 ), PTPN22( 11 ), and other genes were found to be associated with GD. In addition, HD 12 
is also related to inheritance of HLA-DR3( 7 ). 13 
 In our previous study, hTSH-R peptide 37 (AA78-94: ISRIYVSIDVTLQQLES) was 14 
demonstrated to be one of the strongest T-cell epitopes in HLA-DR3 transgenic mice, and was an 15 
important epitope in the early phase of the immunogenic reaction ( 5 ), however, little information 16 
is known about B-cell epitopes using DR3 transgenic mice immunized to hTSH-R-ECD protein or 17 
peptides. 18 
 In an HLA molecule, the anchoring side chains of the peptides (positions 1, 4, 6, 7, and 9) 19 
bind in the HLA-DR binding groove.  Side chains of amino acids in positions 2, 3, 5, and 8 are 20 
believed to contact the T cell receptor (TCR), activate CD4+ T-cells, and eventually B-cells are 21 
driven to produce antibodies (12). 22 
 Many studies showed immune suppression by using altered ligand peptides (ALP) in 23 
autoimmune diseases.  For example, mutated MBP peptides were found to antagonize T-cell 24 
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reactions in Multiple sclerosis ( 13 ). To induce tolerance of CD4+T-cells by attenuating binding to 1 
TCR, we designed a mutated hTSH-R peptide 37 (ISRIYVSIDATLSQLES: 37m) using a computer 2 
algorithm.  In 37m, amino acids in position 5 and 8 were altered from those in hTSH-R peptide 37 3 
(ISRIYVSIDVTLQQLES)( 6 ).  37m was expected to bind to HLA-DR3 firmly, but not bind well 4 
to TCR. 5 
 In the current study, 1) we demonstrate distributions and characteristics of anti-hTSH-R-6 
ECD antibodies in DR3 transgenic mice immunized to hTSH-R-ECD protein or peptides, 2) and we 7 
demonstrate inhibitory effects of mutant hTSH-R peptide to B-cell and T-cell reactions.  We seek 8 
the possibility of an immunological treatment for GD, based on epitope recognition in DR3 9 
transgenic mice. 10 
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Materials and Methods 1 
Mice transgenic for HLA-DR3 2 
 Mice transgenic for HLA-DR3 were generated by Dr. Chella David of the Mayo Clinic ( 14 3 
), and supplied through his courtesy.  The mice have approximately 75% of Black/6, and 10% of 4 
CBA and Black 10 genes.  Mice PBMC were stained with FITC-labeled anti-HLA-DR antibody 5 
(BD Bioscience, San Jose, CA). Mice expressing HLA-DR on more than 20% on their PBMC were 6 
used for studies.  All studies were performed under a protocol approved by the Institutional 7 
Animal Care Committee (IACUC) 8 
Peptide synthesis 9 
 Forty-one 14-20mer hTSH-R-ECD peptides were synthesized as previously described ( 6 ).  10 
Peptides 32-41 were predicted to have high binding affinity to HLA-DR3 or multiple HLA-DRs, 11 
based on EpiMatrix program analysis( 4,6 ).  In addition, a mutated hTSH-R-ECD peptide 37, 12 
named 37m (ISRIYVSIDATLSQLES) was generated. This peptide has two sites of mutation 13 
(peptide-DR3 binding position 5 :V to A,and 8: Q to S ) intended to diminish the peptide binding 14 
affinity to TCR(Table 1).  The sequences of all peptides and purity were confirmed by reverse 15 
phase HPLC, and purity was 90-95%. 16 
Preparation of human recombinant hTSH-R-ECD protein 17 
 hTSH-R-ECD protein was generated from recombinant baculovirus ( 5 )( Chesapeake 18 
Protein Expression and Recovery Labs, Savage, MD).  hTSH-R 19-417 cDNA was sequenced, and 19 
cloned into baculovirus protein expression system.  Trichoplusia ni (cabbage looper caterpillar) 20 
were infected with the recombinant virus.  After 96 hours (in 26C and 70% humidity), larvae were 21 
harvested, and recombinant hTSH-R-ECD was purified through immobilized nickel affinity 22 
chromatography, and dialyzed against phosphate-buffered saline.  Protein purity was analyzed by 23 
SDS-PAGE electrophoresis as a single 55kD band. Average yield was 0.5 mg/dl in PBS. Protein 24 
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concentration was measured by using BCA protein assay kit (Thermo Scientific, Rockford, IL). 1 
Immunization of DR3 transgenic mice to hTSH-R-ECD protein / peptides   2 
 For immunization with hTSH-R-ECD protein (N=11), 25 ug of protein was emulsified in 3 
100ul of complete Freund's adjuvant (CFA, Sigma, St. Louis, MO), and given at tail base on day 0, 4 
followed by three sc injections of protein in 100ul of incomplete Freund's adjuvant (IFA) on days 7, 5 
14, and 21 in groin.  hTSH-R-ECD peptide immunization was performed using 25 ug of each 6 
peptides in the same intervals and methods.  Mice were killed on day 28 ( 5 ).  hTSH-R peptide 7 
37(high immunogenicity, N=6), or peptide 32(AA105-118)(low immunogenicity, N=4)( 4 ) was 8 
used for immunization, and the same amount of PBS emulsified in CFA or IFA (N=7) was used as a 9 
control immunization in the same intervals and methods. 10 
Inhibition of B-cell and T-cell immune response by mutant peptide 11 
 DR3 transgenic mice were divided into 5 groups as follows.  Each group consisted of 4 12 
mice.  The mice were immunized at the same intervals as in the experiment above.  First 13 
immunization was injected at tail base, others sc in groin.  First dose was emulsified in 100 ul of 14 
CFA, and others in the same amounts of IFA: Group A), Immunize mice with 25ug of hTSH-R-15 
ECD protein: Group B), Immunize mice with 25ug of hTSH-R-ECD protein + 25ug of 37m: Group 16 
C), Immunize mice with 25ug of hTSH-R peptide 37: Group D), Immunize mice with 25ug of 17 
hTSH-R peptide 37 + 25ug of 37m: Group E), Immunize mice with 25ug of 37m. 18 
Cell proliferation assay 19 
 105 splenocytes were incubated in each well of round bottom microplates with or without 20 
10 ug/ml antigens.  1uCi of [3H]-thymidine was added to each well.  After 72 hours incubation, 21 
[3H]-thymidine incorporation was measured by liquid scintillation counting.  Results were 22 
expressed as a stimulation index; the ratio of [3H]-thymidine uptake in samples with antigen, to 23 
samples incubated without antigen. Various concentration of hTSH-R 37 peptide were added to 24 
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observe response of splenocytes from immunized mice. All assays were done in triplicate for each 1 
epitope studied.  Data presented in figures are average stimulation index (SI) of all mice in the 2 
group for each epitope.  Experiments were repeated 3 times, and representative studies are 3 
presented.  4 
Thyroid function tests 5 
Serum total T4 and TSH concentrations were measured as previously described (15). Briefly, 6 
Serum total T4 concentration were measured with radioimmunoassay(RIA)(Diagnostic Products, 7 
Los Angeles, CA) using 25µl mouse serum. Serum TSH concentration was assayed using a double 8 
antibody precipitation RIA in 50 µl serum. 9 
ELISA of mouse sera 10 
 Forty-one peptides covering the entire hTSH-R-ECD were used to coat 96 well plates using 11 
1 ul of 5 ug/ml solution diluted to 50 ul in PBS-0.1% TritonX-100, each in triplicate ( 4-6 ).  12 
hTSH-R-ECD protein was diluted in the same buffer as hTSH-R-ECD peptides and used to coat 96 13 
well plates (250 ng/50 ul/ well) overnight at 4C.  After washing with washing buffer (PBS-0.05% 14 
Tween 20), the plates were blocked with 5% BSA in PBS at RT.  Sera were diluted to 1:1000 in 15 
PBS, 0.05% Tween 20, 3% BSA, and 1mM EDTA, and 50ul of aliquots were added to each well.  16 
After incubation for 3 hour at RT, the plates were washed with washing buffer, and 50 ul of a 17 
1:1000 dilution of peroxidase-labeled goat anti-mouse Fc were added to each well.  After 1 hour at 18 
RT, the wells were washed, and 75 ug o-phenylenediamine dihydrochloride-H2O2 solution was 19 
added as substrate.  The reactions were stopped with 50ul of 1M H2SO4, and absorbance at 450mm 20 
was determined. 21 
       For peptide inhibition assays, 1 ul aliquots from 5mg/ml stock of each peptide was added 22 
to the diluted sera during incubation on the antigen-coated plate.  The same amount of hTSH-R-23 
ECD protein was used in the blocking experiments. As a control, PBS with no antigen was used to 24 
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coat the ELISA plate (Fig.2). 1 
Statistical analysis 2 
 For analysis of comparison with each experiment in ELISA (Fig1,Fig.2) or T-cell 3 
stimulation test (Fig.3), Student’s t-test was conducted.  In each test, p-value was examined, and p-4 
value <0.05 was indicated as a significant value. 5 
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Results 1 
 DR3 transgenic mice immunized to recombinant hTSH-R-ECD protein or peptides were 2 
generated as an AITD model.  Serum anti hTSH-R-ECD protein antibody, or anti hTSH-R-ECD 3 
peptide antibodies were titrated by ELISA to recognize B cell epitopes.  Serum T4 and TSH value 4 
were measured as thyroid function tests for these mice. To evaluate inhibition of T-cell response 5 
induced by 37m, mice splenocytes were prepared, and cultured with peptide antigens in vitro. 6 
Anti-hTSH-R-ECD antibodies from DR3 transgenic mice immunized to hTSH-R-ECD protein7 
 DR3 transgenic mice were immunized to hTSH-R-ECD protein, to induce immunity to 8 
hTSH-R antigen (Fig.1A).  After 4 times immunization in CFA or IFA, 63.6% of mice developed 9 
anti-hTSH-R-ECD antibody measured on ELISA, although thyroid function was mostly normal 10 
(Table 2).  Average serum TSH value (73.09+-55.05 mIU/l, normal range: 18-180) was not 11 
suppressed, and T4 concentration (4.77+-0.83 ug/dl, normal range: 3.5-5.5) was not elevated. 12 
 Antisera from the mice reacted strongly with hTSH-R-ECD peptides 1 to 5, covering amino 13 
acid residues 20-94, as shown in (Fig.1A).  In addition, hTSH-R-ECD peptides 21 (258-277), 41 14 
(283-297), 36 (376-389), and 31 (399-418) bound the antisera.  Inhibition of antibody binding to 15 
peptides by hTSH-R-ECD protein, the immunizing protein, was not obtained for binding in the 16 
amino-terminal peptides, perhaps because of relatively insufficient amounts of hTSH-R-ECD were 17 
used to compete with strong antibody binding.  In contrast, added hTSH-R-ECD protein 18 
significantly inhibited binding of antisera to the carboxy-terminal peptides 36(376-389) and 31(399-19 
418). Binding of antisera to hTSH-R peptide 21(258-277) was not inhibited by immunizing antigen.  20 
As expected, adding the same peptide used for coating the wells effectively inhibited binding of the 21 
antibody to all peptides.   22 
Anti-hTSH-R-ECD antibodies from DR3 transgenic mice immunized to hTSH-R-ECD peptides 23 
 24 
10 
 
 Then HLA-DR3 transgenic mice were immunized to hTSH-R peptide 37, 50% of mice 1 
developed anti-hTSH-R-ECD antibody measured on ELISA. Serum TSH value (47.0+-5.29 mIU/l) 2 
and T4 concentration (4.19+-0.22 ug/dl) were within normal ranges. Antisera raised to hTSH-R 3 
peptide 37 (AA 78-94) provided striking results (Fig.1B), with strong binding to the same peptides 4 
to which hTSH-R-ECD protein antisera bound, and in addition to a more extensive set of peptides.  5 
The antisera bound to hTSH-R peptides 1-7 with AA 20-112, peptide 10 (132-150), 33 (137-150), 6 
41 (283-297), 23 (286-305), 24 (301-320), 29 (376-389), and 31 (399-418), as well as to hTSH-R-7 
ECD.  hTSH-R-ECD protein inhibited the responses significantly (30-70%).  Binding to peptides 8 
was mildly inhibited by adding the same peptide to the wells, except for complete inhibition of 9 
binding to hTSH-R peptide 37. 10 
 When DR3 transgenic mice were immunized to hTSH-R peptide 32,a less immunogenic 11 
peptide,  50% of mice developed anti-hTSH-R-ECD antibody measured on ELISA(Table 2).  12 
Serum TSH values (66.5+-19.84 mIU/l) and T4 concentrations (3.54+-0.76 ug/dl) were normal. The 13 
mice developed similar but weaker responses to multiple peptides (1, 2, 3, 4, 5, 32, 13, 21, 34, 35, 14 
and 36), many the same as with hTSH-R peptide 37)(Fig.1C). 15 
 We also checked antibody response by using non-hTSH-R peptides, and none of the 16 
peptides bound anti hTSH-R peptides or protein antibodies.  Further, cross reaction (one peptide 17 
inhibiting binding to a different peptide) also was not seen.  In PBS immunized mice, antisera did 18 
not react with hTSH-R-ECD protein or peptides (Fig.1D). Serum TSH value (96.42+-52.35 mIU/l) 19 
and T4 concentration (4.82+-0.31 ug/dl) were normal in these mice. 20 
 We compared the number of sequence differences between mice / human peptides to 21 
ELISA OD450mm values, and no correlation was found in any group of mice (data not shown ). 22 
Effect of peptide 37m on immunity induced by hTSH-R-ECD or hTSH-R 37 23 
 hTSH-R peptide 37 (AA 78-94) is an important immunogenic peptide in DR3 transgenic 24 
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mice ( 4-6 ). Based on an informatics analysis we have identified the 9-mer frame at amino acid 1 
position 83 as the most likely restricting element. In order to test our theory we designed a mutant 2 
peptide which retains its specificity for DR3 but which lacks the outward facing contour recognized 3 
by T cells reacting to hTSH-R peptide 37. The mutant peptide (ISRIYVSIDATLSQLES: 37m) has 4 
been modified at positions 87 (V87A) and 90 (Q90S); TCR facing positions 5 and 8 within the 5 
restricting 9-mer. In both cases the native amino acid was replaced by another amino acid having 6 
similar chemical properties but less bulk. 7 
37m was predicted to bind to HLA-DR3, but not bind to TCR.  To confirm binding 8 
affinity, EpiMatrix computer algorithm predicted a binding z-score of 37m (z=2.05) to DR3, the 9 
same as hTSH-R peptide 37.  Further, in vitro peptide binding assay using our standard method ( 4 10 
), showed IC50 of 37m to DR3 was 0.3 uM and similar to IC50 of hTSH-R peptide 37. 11 
 Anti hTSH-R protein antibody and anti hTSH-R peptide 37 antibodies were measured with 12 
ELISA (Fig.2).  Co immunization of 37m with hTSH-R peptide 37 did not inhibit development of 13 
antibodies reacting to hTSH-R-ECD).  Mice immunized to hTSH-R peptide 37 produced anti 14 
hTSH-R peptide 37 antibody, however, mice immunized with hTSH-R peptide 37 and 37m did not 15 
develop anti hTSH-R peptide 37 antibody (P<0.01).  No mouse in any group, including mice 16 
immunized only to 37m, developed antibody for 37m.   17 
 We also evaluated T-cell responses in splenocytes of DR3 transgenic mice immunized with 18 
hTSH-R-ECD protein or hTSH-R-ECD peptides by proliferation assays (Fig.3).  Reaction of 19 
splenocyte to hTSH-R peptide 37 was not inhibited in mice immunized to hTSH-R-ECD protein 20 
together with 37m, or mice immunized to hTSH-R-ECD (NS).  Reaction of splenocytes to hTSH-21 
R peptide 37 was significantly reduced in mice co-immunized to hTSH-R peptide 37 plus 37m, 22 
compare to mice immunized to hTSH-R peptide 37 alone, when using 10ug of antigen (Fig.3C)(SI: 23 
P<0.01). Mice immunized to 37m did not produce significant reaction. 24 
12 
 
Discussion  1 
 The etiologies of AITD including GD and HT have been extensively explored, and the 2 
relationship to HLA-DR and TSH-R has been identified ( 1,7 ).  HLA-DR3 has an important 3 
immunological role predisposing to both GD and HT ( 7 ).  Although many studies have been done 4 
on conformational and linear epitopes of anti-hTSH-R antibody ( 16-24), no studies have identified 5 
B-cell epitopes of TSH-R in relation to HLA-DR3.  In this study, we have examined the B-cell 6 
immune response of HLA-DR3 transgenic mice immunized to hTSH-R-ECD or peptides.  B-cell 7 
epitopes appearing predominantly on N-terminus of hTSH-R in the mice were quite similar to those 8 
of non-DR transgenic mice.  Further, a mutated hTSH-R peptide 37 was generated, and by using 9 
the mutated peptide together with immunonegic hTSH-R peptide 37, a partially effective immuno 10 
suppression of B-cell and T-cell responses was obtained. 11 
Thyroid function tests 12 
Based on the results of TSH and T4 assays, thyroid function was not changed in any group 13 
(Table 2), and TSH levels were not correlated with anti-hTSH-R antibody titers. 14 
Immunological response of DR3 mice to hTSH-R-ECD protein or peptides  15 
Our results using DR3 transgenic mice are confirmatory of anti-TSH-R antibody 16 
preferentially binding to the N-terminus of hTSH-R (16-18)(Fig.1A-C). We previously reported 17 
development of TSAb in mice immunized to hTSH-R-ECD peptides ( 19).  Endo, et al. also 18 
confirmed production of TSAb in rabbits immunized to N-terminus of hTSH-R peptide ( 16 ).  19 
Recently, Chazenbalk reported that hTSH-R A subunit (17-228), not whole hTSH-R, is 20 
preferentially recognized by TSAb in GD patients ( 20 ). In some mouse models of GD, 21 
immunization with hTSH-R A subunit effectively induce hyperthyroidism ( 21 ).  These reports 22 
indicate that hTSH-R A subunit, especially N-terminus region, contains immunogenic sequences for 23 
production of TSAb. In the current study, DR3 transgenic mice immunized to hTSH-R-ECD protein 24 
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produced anti-hTSH-R antibody preferentially bound to hTSH-R amino acids 20-94(Fig.1A), 1 
reported as B-cell epitopes that react with TSAb ( 16,17 ), however, thyroid function was normal 2 
(Table 2).  This suggested that the antibodies were primarily binding but not stimulatory. hTSH-R 3 
peptide 21 (22), and peptides in the carboxy–terminal portion of the ECD (23,24) were other B-cell 4 
epitopes in these mice, containing the sequences of binding site forTSBAb/TSH. 5 
 hTSH-R-ECD protein, the immunizing protein, did not inhibit binding of anti hTSH-R-6 
ECD peptides antibodies for binding in the amino-terminal peptides, perhaps because of low cross-7 
reaction to the antibodies against each peptide, or an insufficient amount of the competing antigen. 8 
In contrast, for reasons unknown, added hTSH-R-ECD protein strongly inhibited binding of anti-9 
hTSH-R peptides in carboxy-terminal antibody in antisera from hTSH-R-ECD immunized mice, 10 
and binding of the antibody to hTSH-R peptide 21(258-277) was increased in the presence of 11 
adding hTSH-R-ECD protein.  Biological significance of antisera binding is shown by the fact that 12 
all responses to epitopes were strongly inhibited by adding the same peptide to the wells (Fig.1A). 13 
 Antisera raised to hTSH-R peptide 37 showed binding to the same peptides to which hTSH-14 
R-ECD protein antisera bound, and also unrelated hTSH-R peptides (Fig.1B).   Comparing 15 
antisera for mice immunized to hTSH-R-ECD, to those immunized to hTSH-R peptide 37, (Fig.1B), 16 
antibody to hTSH-R peptide 21 was seen only in hTSH-R-ECD protein immunized mice.  hTSH-17 
R-ECD protein inhibited the responses significantly (approximately 30-70%), indicating reaction of 18 
anti-peptide antibody to hTSH-R protein.  Binding to peptides by anti hTSH-R peptide 37 antisera 19 
was not inhibited by adding the same peptide to the wells, except for complete inhibition of binding 20 
to hTSH-R peptide 37.  This probably relates to differences in affinities of the antisera to the 21 
individual peptide linear antigens. 22 
It is difficult to explain with certainty why hTSH-R peptide 37 induced antibodies reacting 23 
with multiple non-related TSH-R peptides.  We hypothesize that the immunization induced 24 
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antibodies reacting with host (mouse) TSH-R, which then led to antisera binding to a broad 1 
spectrum of mTSH-R epitopes, which overlapped binding with anti-hTSH-R-ECD responses. 2 
Otherwise it is difficult to understand how the mice could have developed responses to TSH-R 3 
peptides to which the animals were not exposed.  Antisera of mice immunized to hTSH-R peptide 4 
32 reacted weakly to multiple hTSH-R peptides(Fig.1C), supporting the idea that hTSH-R peptide 5 
32 is a low immunogenic peptide( 4-6 ).   6 
hTSH-R 317-366 is reported to be excised during secretion of hTSH-R A subunit into 7 
circulation (18,21).  None of mice in the the different immunization groups produced antibodies to 8 
this region, perhaps because of low immunogenicity of the section.    9 
The amino acid residue homology between mouse TSH-R and human TSH-R is 86.25%.  10 
Among our synthesized hTSH-R peptides, peptide 13, 19, 21, 22, 23, 34, 40, and 41 have identical 11 
amino acid sequences to mouse TSH-R.  Other hTSH-R peptides have one or more differences 12 
from mouse TSH-R sequences (Table 1).  We compared the number of differences between mice / 13 
human peptides to ELISA OD450mm values, and no correlation was found in any mice, suggesting 14 
no relationship between the difference in species and the ability to produce antibodies (data not 15 
shown). 16 
Flynn et al. found that HLA-DR3 transgenic mice became hyperthyroid and showed 17 
thyroiditis after injection of hTSH-R-ECD DNA ( 14 ).  Pichurin et al., showed that hTSH-R 18 
amino acids 142-161 possibly include a major T cell epitope in DR3 transgenic mice immunized to 19 
adenovirus coding hTSH-R A-subunit ( 25 ).  In our study, hTSH-R 37 (AA 78-94) was indicated 20 
as one of the strongest epitopes.  The reason for differences of T-cell response among studies is 21 
not known.  Other reports show a change of thyroid function due to transition of stimulation to 22 
blocking anti TSH-R antibodies ( 26 ), as is seen clinically in patients with AITD. Thus, thyroid 23 
function in these mice may change in the course in our study. 24 
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Effect of peptide 37m on immunological responses induced by hTSH-R peptide 37 1 
 In the experiment using 37m, production of anti hTSH-R antibody in the mice immunized 2 
to hTSH-R-ECD protein was not suppressed by the presence of 37m (Fig.2).  However, anti-3 
hTSH-R peptide 37 antibody induced by hTSH-R peptide 37 immunization was significantly 4 
inhibited when immunized together with 37m (Fig.2).  This suggested that B-cell function induced 5 
with hTSH-R peptide 37 was partially suppressed, by competitive binding of 37m to HLA-DR3, 6 
and thus reducing presentation of peptide 37 to TCR. 7 
 In our current study, splenocytes from mice immunized to hTSH-R-ECD reacted to hTSH-8 
R-ECD, and the reaction was not inhibited with addition of 37m (Fig.3).  In contrast, splenocyte 9 
reaction to hTSH-R peptide 37 from mice immunized to hTSH-R peptide 37 was significantly 10 
reduced with addition of 37m (Fig.3).  The reason for this is considered to be an effect of 11 
competitive binding inhibition of 37m described above.  This fact supports another study using 12 
mutant peptides having inhibitory effect for cell proliferation ( 13 ). 13 
 In our previous report on AITD, hTSHR-ECD induced T-cell response strongly to hTSH-R 14 
peptide 37 and weakly to hTSH-R peptide 41 by 2 weeks ( 5 ).  Further, 4 weeks after 15 
immunization, B-cell produced antibodies to multiple hTSH-R peptides (Fig.1A), while T-cells 16 
responded preferentially to hTSH-R peptide 37 ( 5 ).  This suggests that B-cell epitope spreading 17 
progressed more rapidly than T-cell epiope spreading. Similarly,  hTSH-R peptide 37 18 
immunization induced T-cell response only to hTSH-R peptide 37 in 4 weeks( 5 ), but drove B-cell 19 
to produce antibodies to multiple peptides (Fig.1B).  This also supports the idea that B-cell epitope 20 
spreading occurs earlier than T-cell epitope spreading in this study.  21 
Usually linear B-cell epitopes are quite distinct from conformational epitope ( 27 ).  We 22 
have demonstated only linear B-cell epitipe for hTSH-R-ECD protein and peptides, so further 23 
studies are required to elucidate conformational and functional B-cell epitopes. 24 
16 
 
 In thymus, T-cells are selected through positive selection and negative selection ( 28 ). 1 
Then progenitor T cells grow acquiring cell surface markers (CD4, CD8, or CD25), and TCR are 2 
rearranged.  Once naïve T-cell meets epitope, by interaction of TCR+TSH-R epitope+HLA-DR 3 
complex, it begins to proliferate.  Then effecter cells (Th1, Th2, or Th17), or regulatory T cells 4 
differentiate.  Our results suggest that in the early phase of immunological reaction, mutant hTSH-5 
R-ECD peptide may bind to HLA-DR, effectively inhibiting T-cell signals.  In other words, when 6 
certain HLA-DR is saturated with bound mutant peptides, programmed (epitope-sensitized) 7 
immunogenic T-cell cannot receive positive signals.  Taken together, administration of the various 8 
mutant hTSH-R-ECD peptides designed for various HLA-DR could in theory be effective for 9 
various HLA-DR carriers. 10 
In conclusion, binding of anti hTSH-R antibodies to the amino-terminal end of the ECD 11 
was confirmed in our DR3 transgenic mice.  In addition, the ability of immunization to a single 12 
peptide to induce antibodies that bind whole TSH-R protein, as well as multiple unrelated peptides, 13 
is a unique observation.  The mechanism may relate to developing immunity to host TSH-R, and 14 
epitope spreading along this antigen.  Finally, immunogenic reaction to hTSH-R peptide 37 could 15 
be partially suppressed by competing peptide 37m, and in theory this might contribute to 16 
immunotherapy of AITD. 17 
17 
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Figure legends 1 
 Fig.1A:  Antisera from DR3 transgenic mice immunized to hTSH-R-ECD protein, were 2 
used to measure antibodies to individual hTSH-R peptides, indicated as OD 450mm value on 3 
ELISA.  Individual hTSH-R-ECD peptides are set in order of sequence from N-terminus of hTSH-4 
R-ECD.  Solid bar represents result of ELISA without inhibition (peptide only), gray bar shows 5 
results with added hTSH-R-ECD (inhibited by hTSH-R-ECD).  White bar indicates experiment 6 
with adding the same peptide as coated on the assay plate (Inhibited by the same pep).  Error bars 7 
represent data + SD. 8 
 Fig.1B:  Antisera from DR3 transgenic mice immunized to hTSH-R-ECD peptide 37 were 9 
used to measure antibody for each anti-hTSH-R peptide, reported as OD 450mm on ELISA, and 10 
with the same binding inhibition studies as in 1A.  11 
 Fig.1C: DR3 transgenic mice immunized to hTSH-R-ECD peptide 32.  ELISA was 12 
performed in the same methods as above.  13 
 Fig.1D:  DR3 transgenic mice immunized to PBS. 14 
 Fig.2:  ELISA on antisera from DR3 transgenic mice immunized to hTSH-R-ECD protein 15 
and peptide 37 with/without 37m. Data are represented with SD as error bars. Anti hTSH-R-ECD 16 
protein or peptide antibody titer is represented as OD 450mm. As a control, PBS with no antigen 17 
was used to coat the ELISA plate. NS: not significant 18 
 Fig.3: Responses of DR3 transgenic mice splenocytes immunized to hTSH-R-ECD protein 19 
and peptide 37 w/wo 37m are shown.  3H incorporation value (cpm) for splenocytes from mice 20 
immunized to PBS, incubated without antigen is selected as control.  SI (stimulation index) is 21 
calculated as measured value/control value. Data are presented with SD as error bars. 22 
 Table 1:  HLA-DR binding affinities of hTSH-R-ECD derived peptides (IC50 in µM) and 23 
binding predictions are shown.  Underline denotes predicted amino acid sequences of the included 24 
23 
 
motif giving its best binding to HLA-DR3. 1 
*1 position shows amino acid position. 2 
*2 DR3 indicates IC50 binding of each hTSH-R peptide to HLA-DR3 (6) 3 
*3 DR3z indicates EpiMatrix predicting binding score to HLA-DR3, and data with above 1.64 4 
means moderate binding prediction (4).  5 
*4 Position Z represents predicted binding site to HLA-DR3. 6 
*5 M/H difference shows the number of difference in TSH-R between mouse / human. 7 
 Table 2:  DR3 transgenic mice serum data for average TSH values+-SD, average T4 8 
values +-SD, average ELISA OD450mm values for anti-hTSH-R-ECD antibody +-SD, and 9 
percentage of mice having ELISA OD450mm value > 0.200 are shown. 10 
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Table 1 1 
position 1* Amino Acid Sequence DR3 2* DR3z *3 Position Z *4 M/H difference*5
1 20-35 GGMGCSSPPCECHQEE >100 1 22-30 5
2 30-49 ECHQEEDFRVTCKDIQRIPS >100 1.3 33-41 4
3 44-62 IQRIPSLPPSTQTLKLIET >100 0.8 44-52 2
4 57-75 LKLIETHLRTIPSHAFSNL >100 1.7 57-65 3
5 70-88 HAFSNLPNISRIYVSIDVT 29 1 70-78 4
6 83-102 VSIDVTLQQLESHSFYNLSK 41.3 2.1 83-91 4
7 97-112 FYNLSKVTHIEIRNTR 42 2 104-112 1
8 109-124 RNTRNLTYIDPDALKE 5.5 0.9 115-123 2
9 119-137 PDALKELPLLKFLGIFNTG >100 0.8 124-132 1
10 132-150 GIFNTGLKMFPDLTKVYST 0.64 2.3 140-148 3
11 145-163 TKVYSTDIFFILEITDNPY 19.3 1.3 154-162 1
12 158-176 ITDNPYMTSIPVNAFQGLC 50 1.2 163-171 2
13 172-186 FQGLCNETLTLKLYN 18.3 1.2 172-180 0
14 183-198 KLYNNGFTSVQGYAFN >100 1.1 185-193 1
15 195-210 YAFNGTKLDAVYLNKN 46.6 1.6 196-204 1
16 207-222 LNKNKYLTVIDKDAFG 40 1.6 214-222 2
17 217-232 DKDAFGGVYSGPSLLD 90 0.9 224-232 2
18 227-242 GPSLLDVSQTSVTALP 45 1.4 229-237 2
19 237-252 SVTALPSKGLEHLKEL >100 0.7 237-245 0
20 248-263 HLKELIARNTWTLKKL 40 1 250-258 2
21 258-277 WTLKKLPLSLSFLHLTRADL 16.7 2 269-277 0
22 272-291 LTRADLSYPSHCCAFKNQKK 14.2 1.8 273-281 0
23 286-305 FKNQKKIRGILESLMCNESS 60 2.6 286-294 0
24 301-320 CNESSMQSLRQRKSVNALNS 46.7 1.2 309-317 6
25 315-334 VNALNSPLHQEYEENLGDSI 33.8 1.4 318-326 8
26 329-348 NLGDSIVGYKEKSKFQDTHN 80 1.6 329-337 10
27 343-362 FQDTHNNAHYYVFFEEQEDE 20 1.6 354-362 5
28 357-376 EEQEDEIIGFGQELKNPQEE 45 1.8 366-374 2
29 371-390 KNPQEETLQAFDSHYDYTIC 18.3 2.5 379-387 2
30 385-404 YDYTICGDSEDMVCTPKSDE 13 1.3 389-397 2
31 399-418 TPKSDEFNPCEDIMGYKFLR >100 1.7 410-418 1
32(like8) 105-118 HIEIRNTRNLTYID 10 1.7 108-116 1
33(like10) 137-150 GLKMFPDLTKVYST 0.2 2.3 140-148 3
34(21-22) 267-282 LSFLHLTRADLSYPSHC 27.6 2 269-277 0
35(26-27) 339-352 EKSKFQDTHNNAHY 37.5 1.7 342-350 7
36(like29) 376-389 ETLQAFDSHYDYTI 25 2.5 379-387 2
37(5-6) 78-94 ISRIYVSIDVTLQQLES 0.3 2.1 83-91 4
37m 78-94* ISRIYVSIDATLSQLES 0.3 2.1 83-91 3
38(7-8) 103-119 VTHIEIRNTRNLTYIDP 17.5 2 104-112 2
39(15-16) 201-217 KLDAVYLNKNKYLTVID >100 2.2 204-212 2
40(21-22) 266-284 SLSFLHLTRADLSYPSHCC 5 2 269-277 0
41(22-23) 283-297 CCAFKNQKKIRGILE >100 2.6 286-294 0
ex1 HSP3-13 KITAYDEEARR 0.3 2.7 5-13  2 
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Table 2 1 
  immunization TSH mIU/l T4 ug/dl ELISA OD ELISAOD450>0.200 
N=11 hTSH-R-ECD 73.09 +- 55.05 4.77+-0.83 0.671+-0.384 63.6% 
N=6 hTSH-R 37 47.0 +- 5.29 4.19+-0.22 0.255+-0.195 50% 
N=4 hTSH-R 32 66.5 +- 19.84 3.54+-0.76 0.232+-0.134 50% 
N=7 control 96.42 +- 52.35 4.82+-0.31 0.096 +- 0.076 0% 
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